Dirk Smith is a Founding Partner of the Cascadia Drug Development Group, a biotech consultancy based in Seattle, Washington and founded in 2017. Dirk was previously a Scientific Director in the Inflammation Research group at Amgen where he led research programs from discovery to clinical testing. He was Global Research Leader for AMG 282, a first-in-class, IL-33 receptor antibody for respiratory disease. He has a strong interest in innate immunity, mucosal biology, human genetics and cytokine-related pharmacology. Prior to Amgen, Dirk was in the Molecular Biology group at Immunex and also performed basic oncology research at The Fred Hutch cancer center. Dirk received his BSc. in Microbiology and Molecular Biology from Washington State University and his MSc. in Genetics from the University of New Hampshire. He has published over 45 scientific research and review articles, granted several patents and frequently invited to speak at international conferences. Dirk serves as an external committee member for WSU and Fred Hutch commercialization funds and is a member of the Life Science Washington Institute’s WIN mentoring program. He teaches a course on Drug Discovery of Biologics for the University of Washington Master’s program in Pharmaceutical Bioengineering.